Wells Fargo believes the company's hyperplasia and depression treatments could each become over $1 billion opportunities.
Neurocrine Biosciences ' drug pipeline is turning a corner and the company will be "knocking on the doors of the large-cap club" soon, according to Wells Fargo. Analyst Mohit Bansal upgraded shares to overweight from equal weight, and raised his price target to $170 from $140, suggesting around 21% upside potential from Tuesday's close. Bansal forecasts the company's congenital adrenal hyperplasia treatment, crinecerfont, will achieve $1.
"We think Crinecerfont is underappreciated as the Street is only giving credit for $500-$700M peak opportunity." Elsewhere in the company's pipeline, Neurocrine's depression drug NBI-1065845, developed in conjunction with Japanese pharmaceutical company Takeda, showed positive results during a phase II trial. Bansal said this drug could open "a whole new chapter" of a $1.2 billion peak sales opoprtunity.
Neurocrine Biosciences Inc Wells Fargo & Co Stock Markets Markets Business Wall Street Breaking News: Investing Business News
South Africa Latest News, South Africa Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Wednesday's analyst calls: Wells Fargo downgrade, Tesla gets a price target cutTesla and a major bank were in focus Wednesday as part of the day's analyst chatter.
Read more »
Tesla stock added to Wells Fargo's short ideas list amid fears of weak Q1Tesla stock added to Wells Fargo's short ideas list amid fears of weak Q1
Read more »
Here are Wells Fargo's top trades for the second quarterWells Fargo is laying out its top names to play as the new quarter kicks off.
Read more »
Philly food service workers threaten to strike at Wells Fargo CenterHundreds of Philly food service workers are threatening to strike against Aramark's operations at the Wells Fargo Center.
Read more »
S&P 500 target raised to 5500+ at Wells Fargo on strong earnings growthS&P 500 target raised to 5500+ at Wells Fargo on strong earnings growth
Read more »
Tuesday's analyst calls: Wells Fargo gets a downgrade, legacy tech stock to pop 20%A major U.S. bank and a legacy tech name were the focus of some of Tuesday's biggest analyst calls.
Read more »